Compare TOI & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOI | RLMD |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.6M | 319.0M |
| IPO Year | N/A | N/A |
| Metric | TOI | RLMD |
|---|---|---|
| Price | $3.07 | $4.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $6.00 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.9M | 541.7K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $461,039,000.00 | N/A |
| Revenue This Year | $28.51 | N/A |
| Revenue Next Year | $23.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.67 | N/A |
| 52 Week Low | $0.60 | $0.24 |
| 52 Week High | $4.88 | $5.12 |
| Indicator | TOI | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 51.73 |
| Support Level | $3.30 | $3.78 |
| Resistance Level | $3.68 | $4.53 |
| Average True Range (ATR) | 0.28 | 0.31 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 2.04 | 57.98 |
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.